Scarica l'app Stockscreener
97.10
1.21%
1.16
Dopo l'orario di chiusura:
97.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Yahoo Finance Singapore
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts - Benzinga
INCY: Today's Analyst Rating Update by HC Wainwright & Co. | INC - GuruFocus
Incyte wins EC approval of Zynyz for SCAC - The Pharma Letter
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
FDA Declines New Indication for Incyte's (INCY) Zynyz Due to Manufacturing Issues - GuruFocus
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant - Seeking Alpha
Incyte Corporation (INCY) Receives FDA Complete Response Letter for Zynyz® sBLA - GuruFocus
FDA issues complete response letter for Incyte’s Zynyz application in lung cancer - Investing.com
Assessing Incyte (INCY) Valuation After Recent Share Price Weakness And Mixed Fair Value Signals - Yahoo Finance
Incyte (INCY) Gains EC Approval for Combination Therapy with Zyn - GuruFocus
FDA issues CRL for Incyte sBLA for Zynyz in NSCLC over third-party facility inspection - TradingView
(retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Business Wire
Incyte Momentum Builds With Strong Cash Flows Ahead Of Key Conference - Yahoo Finance
Today's Analyst Rating Update on Incyte (INCY): Evercore ISI Gro - GuruFocus
Incyte Corporation $INCY Shares Bought by Victory Capital Management Inc. - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Teachers Retirement System of The State of Kentucky Has $30.18 Million Stake in Incyte Corporation $INCY - MarketBeat
INCY Earnings History & Surprises | EPS & Revenue Results | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte at TD Cowen Conference: Strategic Growth Beyond Jakafi By Investing.com - Investing.com Canada
Incyte at TD Cowen Conference: Strategic Growth Beyond Jakafi - Investing.com
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
TD Asset Management Inc Increases Position in Incyte Corporation $INCY - MarketBeat
Incyte to Present at Three March Investor Conferences - MyChesCo
Incyte (INCY) Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential - simplywall.st
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Lilly and Incyte’s Olumiant Recommended in EU for Adolescents with Severe Alopecia Areata - Contract Pharma
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Andra AP fonden Boosts Stake in Incyte Corporation $INCY - MarketBeat
NICE backs approval for Incyte’s Opzelura - The Pharma Letter
Incyte Earnings Underscore Shift From Jakafi Reliance To Broader Pipeline - Yahoo Finance
INCYTE (INCY) R&D president exercises options, sells 18,668 shares at $100.91 - Stock Titan
Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals - ChartMill
Incyte Stock Fell 7% Last Week. Here’s What the Rest of 2026 Could Look Like - TIKR.com
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales - Finviz
Aberdeen Group plc Grows Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Reports $5.14 Billion in 2025 Revenue, Issues 2026 Outlook - MyChesCo
Where is Incyte Corporation (INCY) Headed According to Analysts? - Finviz
Barclays Analyst Raises Price Target for Incyte (INCY) to $117 | - GuruFocus
Incyte (INCY) Expands Latin American Partnership with Knight The - GuruFocus
The Top 5 Analyst Questions From Incyte's Q4 Earnings Call - Finviz
Incyte to Present at Upcoming Investor Conferences - Business Wire
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call - Yahoo Finance
Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally? - Smartkarma
Do Wall Street analysts like Incyte Corporation stock? - MSN
INCY Q4 earnings miss estimates, revenues beat on higher product sales - MSN
Cookson Peirce & Co. Inc. Acquires Shares of 11,331 Incyte Corporation $INCY - MarketBeat
Incyte’s weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10) By Reuters - Investing.com
Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns - Reuters
Is It Too Late To Consider Incyte (INCY) After Its 43% One Year Rally - Yahoo Finance
Incyte Corporation $INCY Shares Sold by Sound Shore Management Inc CT - MarketBeat
1.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):